Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489593 · ClinicalTrials.gov registry record · Phase 1
Olanzapine in Patients With Advanced Cancer and Weight Loss
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00489593: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00489593 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489593, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the drug Olanzapine that can be given to patients with advanced cancer who are experiencing weight loss. Researchers want to find out if Olanzapine can help decrease weight loss in patients who are experiencing it because of cancer. How this drug affects performance status, cancer-related symptoms, and nutritional status in patients with advanced cancer will also be studied.
Interventions
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2006-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489593
The ClinicalTrials.gov registry entry for NCT00489593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olanzapine is the first listed.
NCT00489593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00489593 about?
NCT00489593 is a clinical study titled "Olanzapine in Patients With Advanced Cancer and Weight Loss". The goal of this clinical research study is to find the highest tolerable dose of the drug Olanzapine that can be given to patients with advanced cancer who are experiencing weight loss. Researchers want to find out if Olanzapine can help decrease weight loss in patients who are experiencing it beca...
What is the current status of trial NCT00489593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2006-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00489593?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00489593?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.